(S)-nicotine increases expression ISO RGD:1349729 6480464 Nicotine results in increased expression of VCAN mRNA CTD PMID:23825647 1-naphthyl isothiocyanate increases expression EXP 6480464 1-Naphthylisothiocyanate results in increased expression of VCAN mRNA CTD PMID:30723492 1-nitropyrene increases expression ISO RGD:1349729 6480464 1-nitropyrene results in increased expression of VCAN mRNA CTD PMID:19041380 17beta-estradiol increases expression ISO RGD:731396 6480464 Estradiol results in increased expression of VCAN mRNA CTD PMID:19484750 , PMID:30077407 17beta-estradiol multiple interactions ISO RGD:731396 6480464 [Polyphenols co-treated with Estradiol] results in increased expression of VCAN mRNA CTD PMID:30077407 17beta-estradiol multiple interactions ISO RGD:1349729 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of VCAN mRNA, [Estradiol co-treated with TGFB1 protein] results in increased expression of VCAN mRNA CTD PMID:20660070 , PMID:30165855 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1349729 6480464 Tetrachlorodibenzodioxin results in increased expression of VCAN mRNA CTD PMID:21998131 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of VCAN mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:731396 6480464 Tetrachlorodibenzodioxin results in increased expression of VCAN mRNA CTD PMID:27562557 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:731396 6480464 Tetrachlorodibenzodioxin affects the expression of VCAN mRNA CTD PMID:18691609 , PMID:26377647 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of VCAN mRNA CTD PMID:22808131 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1349729 6480464 Tetrachlorodibenzodioxin results in decreased expression of VCAN mRNA CTD PMID:20106945 , PMID:21632981 2,4,6-trinitrobenzenesulfonic acid multiple interactions ISO RGD:731396 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of VCAN mRNA] CTD PMID:18200517 2,4,6-trinitrobenzenesulfonic acid increases expression ISO RGD:731396 6480464 Trinitrobenzenesulfonic Acid results in increased expression of VCAN mRNA CTD PMID:18200517 2-amino-2-deoxy-D-glucopyranose multiple interactions EXP 6480464 Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA], IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] CTD PMID:17109745 2-amino-2-deoxy-D-glucopyranose decreases expression EXP 6480464 Glucosamine results in decreased expression of VCAN mRNA CTD PMID:17109745 3'-amino-3'-deoxy-N(6),N(6)-dimethyladenosine decreases expression ISO RGD:1349729 6480464 Puromycin Aminonucleoside results in decreased expression of VCAN mRNA, Puromycin Aminonucleoside results in decreased expression of VCAN protein CTD PMID:15585670 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:731396 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of VCAN mRNA CTD PMID:16054899 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO RGD:1349729 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of VCAN mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of VCAN mRNA CTD PMID:28628672 4,4'-diaminodiphenylmethane increases expression EXP 6480464 4, 4'-diaminodiphenylmethane results in increased expression of VCAN mRNA CTD PMID:30723492 4,4'-sulfonyldiphenol increases expression ISO RGD:731396 6480464 bis4-hydroxyphenylsulfone results in increased expression of VCAN mRNA CTD PMID:30951980 4-hydroxyphenyl retinamide decreases expression ISO RGD:731396 6480464 Fenretinide results in decreased expression of VCAN mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine affects expression ISO RGD:1349729 6480464 Decitabine affects the expression of VCAN mRNA CTD PMID:23300844 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of VCAN mRNA CTD PMID:24780913 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of VCAN mRNA CTD PMID:28959563 aflatoxin B1 affects expression ISO RGD:1349729 6480464 Aflatoxin B1 affects the expression of VCAN protein CTD PMID:20106945 aflatoxin B1 increases methylation ISO RGD:1349729 6480464 Aflatoxin B1 results in increased methylation of VCAN intron CTD PMID:30157460 aflatoxin B1 increases expression ISO RGD:1349729 6480464 Aflatoxin B1 results in increased expression of VCAN mRNA CTD PMID:22100608 , PMID:32234424 aflatoxin M1 decreases expression ISO RGD:1349729 6480464 Aflatoxin M1 results in decreased expression of VCAN mRNA CTD PMID:30928695 aldehydo-D-glucosamine multiple interactions EXP 6480464 Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA], IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] CTD PMID:17109745 aldehydo-D-glucosamine decreases expression EXP 6480464 Glucosamine results in decreased expression of VCAN mRNA CTD PMID:17109745 all-trans-retinoic acid increases expression ISO RGD:1349729 6480464 Tretinoin results in increased expression of VCAN mRNA CTD PMID:23724009 amphetamine increases expression EXP 6480464 Amphetamine results in increased expression of VCAN mRNA CTD PMID:30779732 arsenite(3-) decreases expression ISO RGD:1349729 6480464 arsenite results in decreased expression of VCAN mRNA CTD PMID:23974009 astemizole decreases expression EXP 6480464 Astemizole results in decreased expression of VCAN mRNA CTD PMID:20221588 benzene increases expression ISO RGD:1349729 6480464 Benzene results in increased expression of VCAN mRNA CTD PMID:19162166 benzo[a]pyrene increases mutagenesis ISO RGD:1349729 6480464 Benzoapyrene results in increased mutagenesis of VCAN gene CTD PMID:25435355 benzo[a]pyrene increases expression ISO RGD:1349729 6480464 Benzoapyrene results in increased expression of VCAN mRNA CTD PMID:32234424 benzo[a]pyrene increases methylation ISO RGD:1349729 6480464 Benzoapyrene results in increased methylation of VCAN 5' UTR more ... CTD PMID:27901495 benzo[a]pyrene decreases expression ISO RGD:1349729 6480464 Benzoapyrene results in decreased expression of VCAN mRNA CTD PMID:21632981 benzo[a]pyrene affects expression ISO RGD:1349729 6480464 Benzoapyrene affects the expression of VCAN mRNA CTD PMID:20106945 beta-D-glucosamine multiple interactions EXP 6480464 Glucosamine inhibits the reaction [IL1B results in increased expression of VCAN mRNA], IL1B affects the reaction [Glucosamine results in decreased expression of VCAN mRNA] CTD PMID:17109745 beta-D-glucosamine decreases expression EXP 6480464 Glucosamine results in decreased expression of VCAN mRNA CTD PMID:17109745 bezafibrate decreases expression ISO RGD:1349729 6480464 Bezafibrate results in decreased expression of VCAN mRNA CTD PMID:11522680 bisphenol A decreases expression ISO RGD:731396 6480464 bisphenol A results in decreased expression of VCAN mRNA CTD PMID:23704952 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of VCAN mRNA CTD PMID:29323181 , PMID:30816183 bisphenol A increases expression ISO RGD:731396 6480464 bisphenol A results in increased expression of VCAN mRNA CTD PMID:30951980 bisphenol A multiple interactions ISO RGD:1349729 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of VCAN mRNA CTD PMID:28628672 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of VCAN gene CTD PMID:28505145 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of VCAN mRNA CTD PMID:25181051 bisphenol F multiple interactions ISO RGD:1349729 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of VCAN mRNA CTD PMID:28628672 bisphenol F increases expression ISO RGD:731396 6480464 bisphenol F results in increased expression of VCAN mRNA CTD PMID:30951980 Brodifacoum increases expression EXP 6480464 bromfenacoum results in increased expression of VCAN protein CTD PMID:28903499 butan-1-ol multiple interactions ISO RGD:1349729 6480464 [[Gasoline co-treated with 1-Butanol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of VCAN mRNA CTD PMID:29432896 butanal decreases expression ISO RGD:1349729 6480464 butyraldehyde results in decreased expression of VCAN mRNA CTD PMID:26079696 cadmium atom decreases expression ISO RGD:1349729 6480464 Cadmium results in decreased expression of VCAN mRNA CTD PMID:23369406 caffeine decreases expression EXP 6480464 Caffeine results in decreased expression of VCAN mRNA CTD PMID:25868845 calcitriol decreases expression ISO RGD:1349729 6480464 Calcitriol results in decreased expression of VCAN mRNA CTD PMID:26485663 carbamazepine affects expression ISO RGD:1349729 6480464 Carbamazepine affects the expression of VCAN mRNA CTD PMID:25979313 carbofuran increases expression EXP 6480464 Carbofuran results in increased expression of VCAN mRNA CTD PMID:20211217 carbofuran decreases expression EXP 6480464 Carbofuran results in decreased expression of VCAN mRNA CTD PMID:30471306 carbon nanotube increases expression ISO RGD:731396 6480464 Nanotubes more ... CTD PMID:25554681 chloropicrin increases expression ISO RGD:1349729 6480464 chloropicrin results in increased expression of VCAN mRNA CTD PMID:26352163 cisplatin affects expression ISO RGD:1349729 6480464 Cisplatin affects the expression of VCAN mRNA CTD PMID:23300844 cisplatin increases expression ISO RGD:1349729 6480464 Cisplatin results in increased expression of VCAN mRNA CTD PMID:27392435 cobalt dichloride decreases secretion ISO RGD:1349729 6480464 cobaltous chloride results in decreased secretion of VCAN protein CTD PMID:22079246 cobalt dichloride decreases expression EXP 6480464 cobaltous chloride results in decreased expression of VCAN mRNA CTD PMID:24386269 cobalt dichloride decreases expression ISO RGD:1349729 6480464 cobaltous chloride results in decreased expression of VCAN mRNA CTD PMID:19376846 copper atom multiple interactions ISO RGD:1349729 6480464 [Disulfiram binds to Copper] which results in increased expression of VCAN mRNA CTD PMID:24690739 copper(0) multiple interactions ISO RGD:1349729 6480464 [Disulfiram binds to Copper] which results in increased expression of VCAN mRNA CTD PMID:24690739 corticosterone decreases expression EXP 6480464 Corticosterone results in decreased expression of VCAN mRNA CTD PMID:15755911 curcumin multiple interactions ISO RGD:731396 6480464 Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of VCAN mRNA] CTD PMID:18200517 cyclosporin A increases expression EXP 6480464 Cyclosporine results in increased expression of VCAN mRNA CTD PMID:21865292 cyclosporin A increases expression ISO RGD:1349729 6480464 Cyclosporine results in increased expression of VCAN mRNA CTD PMID:25562108 decabromodiphenyl ether decreases expression EXP 6480464 decabromobiphenyl ether results in decreased expression of VCAN mRNA CTD PMID:23640034 deoxynivalenol decreases expression ISO RGD:1349729 6480464 deoxynivalenol results in decreased expression of VCAN mRNA CTD PMID:31863870 dexamethasone multiple interactions ISO RGD:731396 6480464 [Dexamethasone co-treated with rosiglitazone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of VCAN mRNA CTD PMID:16054899 dexamethasone multiple interactions ISO RGD:1349729 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of VCAN mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of VCAN mRNA CTD PMID:28628672 dexamethasone decreases expression ISO RGD:1349729 6480464 Dexamethasone results in decreased expression of VCAN mRNA CTD PMID:25047013 dexamethasone increases expression ISO RGD:731396 6480464 Dexamethasone results in increased expression of VCAN mRNA CTD PMID:22733784 dextran sulfate multiple interactions ISO RGD:731396 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VCAN mRNA CTD PMID:29950665 dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of VCAN mRNA CTD PMID:21266533 diclofenac decreases expression ISO RGD:731396 6480464 Diclofenac results in decreased expression of VCAN mRNA CTD PMID:26934552 dimethylarsinous acid decreases expression ISO RGD:1349729 6480464 dimethylarsinous acid results in decreased expression of VCAN mRNA CTD PMID:23876855 dioxygen multiple interactions ISO RGD:731396 6480464 [baysilon results in increased abundance of Oxygen] which results in increased expression of VCAN mRNA, [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of VCAN mRNA CTD PMID:29156398 , PMID:30529165 dioxygen increases expression ISO RGD:1349729 6480464 Oxygen deficiency results in increased expression of VCAN mRNA CTD PMID:26516004 disulfiram multiple interactions ISO RGD:1349729 6480464 [Disulfiram binds to Copper] which results in increased expression of VCAN mRNA CTD PMID:24690739 diuron decreases expression EXP 6480464 Diuron results in decreased expression of VCAN mRNA CTD PMID:25152437 dopamine increases expression EXP 6480464 Dopamine results in increased expression of VCAN mRNA CTD PMID:21983523 dorsomorphin multiple interactions ISO RGD:1349729 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 doxorubicin increases expression ISO RGD:731396 6480464 Doxorubicin results in increased expression of VCAN mRNA CTD PMID:19073829 doxorubicin decreases expression ISO RGD:1349729 6480464 Doxorubicin results in decreased expression of VCAN mRNA CTD PMID:29803840 doxorubicin increases expression EXP 6480464 Doxorubicin results in increased expression of VCAN mRNA CTD PMID:20211217 doxorubicin decreases expression ISO RGD:731396 6480464 Doxorubicin results in decreased expression of VCAN protein CTD PMID:19073829 ethanol decreases expression ISO RGD:1349729 6480464 Ethanol results in decreased expression of VCAN mRNA CTD PMID:28986285 ethanol increases expression ISO RGD:731396 6480464 Ethanol results in increased expression of VCAN mRNA CTD PMID:30319688 etoposide affects response to substance ISO RGD:1349729 6480464 VCAN protein affects the susceptibility to Etoposide CTD PMID:16217747 fenoldopam increases expression EXP 6480464 Fenoldopam results in increased expression of VCAN mRNA CTD PMID:21983523 fenvalerate increases expression EXP 6480464 fenvalerate results in increased expression of VCAN mRNA CTD PMID:30307764 furan increases expression EXP 6480464 furan results in increased expression of VCAN mRNA CTD PMID:27387713 hexadecanoic acid multiple interactions ISO RGD:1349729 6480464 [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA, [Palmitic Acid co-treated with Oleic Acid] affects the expression of VCAN mRNA CTD PMID:30547786 indometacin multiple interactions ISO RGD:1349729 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in decreased expression of VCAN mRNA, [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of VCAN mRNA CTD PMID:28628672 isoprenaline increases expression EXP 6480464 Isoproterenol results in increased expression of VCAN mRNA CTD PMID:20211217 isotretinoin increases expression ISO RGD:1349729 6480464 Isotretinoin results in increased expression of VCAN mRNA CTD PMID:20436886 ketamine decreases expression EXP 6480464 Ketamine results in decreased expression of VCAN mRNA CTD PMID:20080153 lead(0) affects splicing ISO RGD:1349729 6480464 Lead affects the splicing of VCAN mRNA CTD PMID:28903495 lead(2+) affects splicing ISO RGD:1349729 6480464 Lead affects the splicing of VCAN mRNA CTD PMID:28903495 mitoxantrone affects response to substance ISO RGD:1349729 6480464 VCAN protein affects the susceptibility to Mitoxantrone CTD PMID:16217747 monosodium L-glutamate decreases expression ISO RGD:731396 6480464 Sodium Glutamate results in decreased expression of VCAN mRNA CTD PMID:22078008 monosodium L-glutamate multiple interactions ISO RGD:731396 6480464 [Trans Fatty Acids co-treated with Sodium Glutamate] results in increased expression of VCAN mRNA CTD PMID:22078008 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1349729 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of VCAN mRNA CTD PMID:24810058 nickel atom increases expression ISO RGD:1349729 6480464 Nickel results in increased expression of VCAN mRNA CTD PMID:24768652 , PMID:25583101 nickel sulfate increases expression ISO RGD:731396 6480464 nickel sulfate results in increased expression of VCAN mRNA CTD PMID:16166746 nickel sulfate decreases expression ISO RGD:1349729 6480464 nickel sulfate results in decreased expression of VCAN mRNA CTD PMID:22714537 nicotine increases expression ISO RGD:1349729 6480464 Nicotine results in increased expression of VCAN mRNA CTD PMID:23825647 oleic acid multiple interactions ISO RGD:1349729 6480464 [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of VCAN mRNA, [Palmitic Acid co-treated with Oleic Acid] affects the expression of VCAN mRNA CTD PMID:30547786 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of VCAN mRNA CTD PMID:25729387 paclitaxel increases expression EXP 6480464 Paclitaxel results in increased expression of VCAN mRNA CTD PMID:18754875 paracetamol decreases expression ISO RGD:1349729 6480464 Acetaminophen results in decreased expression of VCAN mRNA CTD PMID:21420995 paracetamol increases expression ISO RGD:1349729 6480464 Acetaminophen results in increased expression of VCAN mRNA CTD PMID:29067470 phenylephrine increases expression EXP 6480464 Phenylephrine results in increased expression of VCAN mRNA CTD PMID:18158353 phenytoin increases expression ISO RGD:1349729 6480464 Phenytoin results in increased expression of VCAN mRNA CTD PMID:14741686 pirinixic acid multiple interactions ISO RGD:1349729 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of VCAN mRNA CTD PMID:19710929 potassium chromate increases expression ISO RGD:1349729 6480464 potassium chromateVI results in increased expression of VCAN mRNA CTD PMID:22714537 progesterone increases expression EXP 6480464 Progesterone results in increased expression of VCAN mRNA CTD PMID:20726854 progesterone increases expression ISO RGD:1349729 6480464 Progesterone results in increased expression of VCAN mRNA CTD PMID:18692832 progesterone multiple interactions ISO RGD:1349729 6480464 [Estradiol co-treated with Progesterone] results in decreased expression of VCAN mRNA CTD PMID:20660070 rofecoxib decreases expression ISO RGD:1349729 6480464 rofecoxib results in decreased expression of VCAN mRNA CTD PMID:17070997 rotenone decreases expression EXP 6480464 Rotenone results in decreased expression of VCAN mRNA CTD PMID:28374803 rotenone decreases expression ISO RGD:1349729 6480464 Rotenone results in decreased expression of VCAN mRNA CTD PMID:29955902 SB 431542 multiple interactions ISO RGD:1349729 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1 more ... CTD PMID:27188386 serpentine asbestos multiple interactions ISO RGD:731396 6480464 SPP1 gene mutant form inhibits the reaction [Asbestos, Serpentine results in increased expression of VCAN mRNA] CTD PMID:21514415 serpentine asbestos increases expression ISO RGD:731396 6480464 Asbestos, Serpentine results in increased expression of VCAN mRNA CTD PMID:21514415 silicon dioxide decreases expression ISO RGD:1349729 6480464 Silicon Dioxide analog results in decreased expression of VCAN mRNA, Silicon Dioxide results in decreased expression of VCAN mRNA CTD PMID:25351596 , PMID:25895662 silicon dioxide increases expression ISO RGD:731396 6480464 Silicon Dioxide results in increased expression of VCAN mRNA CTD PMID:23221170 , PMID:29341224 silicon dioxide increases expression ISO RGD:1349729 6480464 Silicon Dioxide analog results in increased expression of VCAN mRNA CTD PMID:23806026 silicon dioxide affects secretion ISO RGD:1349729 6480464 Silicon Dioxide analog affects the secretion of VCAN protein CTD PMID:25895662 silver atom decreases expression ISO RGD:1349729 6480464 Silver results in decreased expression of VCAN mRNA CTD PMID:26551752 silver(0) decreases expression ISO RGD:1349729 6480464 Silver results in decreased expression of VCAN mRNA CTD PMID:26551752 sirolimus increases expression EXP 6480464 Sirolimus results in increased expression of VCAN mRNA CTD PMID:21865292 sodium arsenite decreases expression ISO RGD:1349729 6480464 sodium arsenite results in decreased expression of VCAN mRNA CTD PMID:23876855 sodium arsenite increases expression ISO RGD:1349729 6480464 sodium arsenite results in increased expression of VCAN mRNA CTD PMID:29301061 sodium arsenite affects methylation ISO RGD:1349729 6480464 sodium arsenite affects the methylation of VCAN gene CTD PMID:28589171 Soman increases expression EXP 6480464 Soman results in increased expression of VCAN mRNA CTD PMID:19281266 sunitinib increases expression ISO RGD:1349729 6480464 Sunitinib results in increased expression of VCAN mRNA CTD PMID:31533062 tacrolimus hydrate increases expression EXP 6480464 Tacrolimus results in increased expression of VCAN mRNA CTD PMID:21865292 tert-butyl hydroperoxide decreases expression ISO RGD:1349729 6480464 tert-Butylhydroperoxide results in decreased expression of VCAN mRNA CTD PMID:15336504 tetrachloromethane affects expression EXP 6480464 Carbon Tetrachloride affects the expression of VCAN mRNA CTD PMID:12734012 titanium dioxide multiple interactions ISO RGD:731396 6480464 [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VCAN mRNA CTD PMID:29950665 topotecan increases expression EXP 6480464 Topotecan results in increased expression of VCAN mRNA CTD PMID:25729387 topotecan affects response to substance ISO RGD:1349729 6480464 VCAN protein affects the susceptibility to Topotecan CTD PMID:16217747 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of VCAN mRNA CTD PMID:25729387 tremolite asbestos increases expression ISO RGD:731396 6480464 tremolite results in increased expression of VCAN mRNA CTD PMID:29279043 trichostatin A increases expression ISO RGD:1349729 6480464 trichostatin A results in increased expression of VCAN mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1349729 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of VCAN mRNA CTD PMID:27188386 triclosan decreases expression ISO RGD:1349729 6480464 Triclosan results in decreased expression of VCAN mRNA CTD PMID:30510588 Triptolide increases expression EXP 6480464 triptolide results in increased expression of VCAN protein CTD PMID:32519852 tris(2-butoxyethyl) phosphate affects expression ISO RGD:1349729 6480464 tris2-butoxyethyl phosphate affects the expression of VCAN mRNA CTD PMID:29024780 troglitazone increases expression ISO RGD:731396 6480464 troglitazone results in increased expression of VCAN mRNA CTD PMID:28973697 troglitazone increases expression ISO RGD:1349729 6480464 troglitazone results in increased expression of VCAN mRNA CTD PMID:19140230 tunicamycin decreases expression ISO RGD:731396 6480464 Tunicamycin results in decreased expression of VCAN mRNA CTD PMID:17127020 tunicamycin increases expression ISO RGD:731396 6480464 Tunicamycin results in increased expression of VCAN mRNA CTD PMID:17127020 valproic acid affects expression ISO RGD:1349729 6480464 Valproic Acid affects the expression of VCAN mRNA CTD PMID:25979313 valproic acid increases expression ISO RGD:1349729 6480464 Valproic Acid results in increased expression of VCAN mRNA CTD PMID:23179753 , PMID:26272509 valproic acid multiple interactions ISO RGD:1349729 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of VCAN mRNA CTD PMID:27188386 valproic acid decreases expression ISO RGD:1349729 6480464 Valproic Acid results in decreased expression of VCAN mRNA CTD PMID:27188386 more ... vorinostat decreases expression EXP 6480464 vorinostat results in decreased expression of VCAN mRNA CTD PMID:20060208 vorinostat increases expression ISO RGD:1349729 6480464 vorinostat results in increased expression of VCAN mRNA CTD PMID:26272509
